Wockhardt: Cessation of Vinesh Kumar Jairath as Non- Executive Independent Director of the company w.e.f. November 09,…
Wockhardt (WOCKPHARMA) filed a disclosure titled "Cessation of Vinesh Kumar Jairath as Non- Executive Independent Director of the company w.e.f. The company is valued at about ₹33,010 crore.
What happened
Wockhardt (WOCKPHARMA) filed a disclosure with the exchanges on 9 November 2026 at 05:58 PM titled "Cessation of Vinesh Kumar Jairath as Non- Executive Independent Director of the company w.e.f. November 09, 2026".
From the filing: "Wockhardt Limited has informed the Exchange regarding Cessation of Vinesh Kumar Jairath as Non- Executive Independent Director of the company w.e.f."
Company snapshot
Wockhardt is a mid-cap company in the Healthcare sector, with a market value of about ₹33,010 crore.
The stock last traded at ₹2,031.5, against a 52-week range of ₹1,086.7–₹2,422.3 (16.1% below the high).
Before this filing the shares had moved −9.5% over the month and −3.7% over three months. Average daily turnover over the last 20 sessions was about ₹129 crore.
Promoters held 49.32% at the end of Q2 FY27, up 0.24% points from the previous quarter; 9.97% of promoter shares were pledged. Foreign institutions owned 7.02% and domestic institutions 9.00%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 782 | 78 | 4.81 |
| Q3 FY26 | 888 | 59 | 3.61 |
| Q4 FY26 | 965 | 166 | 10.23 |
| Q1 FY27 | 929 | 106 | 6.55 |
| Q2 FY27 | 969 | 79 | 4.85 |
What history shows
BCEIE's records show 1 previous management change filing from the company since May 2026.
Across 126 similar disclosures by other Healthcare companies, shares moved +1.0% on average the next day and +1.8% over five days; 49% of them rose the next day.
Market-wide, 4,332 management change filings with an impact score of 50 or more saw an average next-day move of −0.0%, with 45% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- The appointment of a successor and any change in strategy or guidance.
In the news
Recent coverage elsewhere (links open the original publisher):
- Wockhardt Q2 net profit falls 11% as Zaynich launch expenses weigh on margins
- Wockhardt Q2 Profit Falls 11% to ₹73 Cr; Revenue Rises 24%
- Wockhardt revenue rises 24% to ₹939 cr in Q2, pre-launch Zaynich spending dents profit
- Wockhardt Q2 Net Profit Declines 11% to Rs 73 Cr
- Wockhardt seeks 14-year data shield for India-made drugs
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.